NVAX Jan 2025 45.000 call
| Previous Close | 0.9700 |
| Open | 1.0500 |
| Bid | 0.9100 |
| Ask | 0.9700 |
| Strike | 45.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.8000 - 1.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 6.97k |
ZacksVaccine Stocks Rise on Growing Threat of Bird Flu Infections
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Barrons.comModerna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
ReutersShah Capital ends campaign against Novavax board after Sanofi deal
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Novavax, which struggled to get its protein-based vaccine to the market in a timely manner, also removed a warning notice from February last year that raised doubts about it being in business after the deal. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".
